1796 Stock Overview
GeneFerm Biotechnology Co., Ltd. develops, manufactures, and sells fermented health care products in Taiwan and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 3/6 |
GeneFerm Biotechnology Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NT$55.80 |
| 52 Week High | NT$158.50 |
| 52 Week Low | NT$53.30 |
| Beta | 0.57 |
| 1 Month Change | -16.59% |
| 3 Month Change | -19.13% |
| 1 Year Change | -52.91% |
| 3 Year Change | 55.00% |
| 5 Year Change | 42.53% |
| Change since IPO | -38.28% |
Recent News & Updates
Shareholder Returns
| 1796 | TW Personal Products | TW Market | |
|---|---|---|---|
| 7D | 1.8% | 1.7% | 2.8% |
| 1Y | -52.9% | -15.3% | 27.4% |
Return vs Industry: 1796 underperformed the TW Personal Products industry which returned -15.3% over the past year.
Return vs Market: 1796 underperformed the TW Market which returned 27.4% over the past year.
Price Volatility
| 1796 volatility | |
|---|---|
| 1796 Average Weekly Movement | 6.7% |
| Personal Products Industry Average Movement | 4.0% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in TW Market | 8.7% |
| 10% least volatile stocks in TW Market | 2.2% |
Stable Share Price: 1796 has not had significant price volatility in the past 3 months.
Volatility Over Time: 1796's weekly volatility (7%) has been stable over the past year, but is still higher than 75% of TW stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1988 | n/a | n/a | www.geneferm.com |
GeneFerm Biotechnology Co., Ltd. develops, manufactures, and sells fermented health care products in Taiwan and internationally. The company offers microbial fermentation products, which includes mushrooms, lactic acid bacteria, bacteria, yeast, and algae; bio fermented ingredients, such as nattomena, natto fermented powder, red yeast rice fermented powder, antrodia cinnamomea mycelia powder, cordyceps, reishi mycelia, phellinus linteus mycelia powder, armillaria mellea mycelia powder, beta-glucan powder, fruits and vegetables fermented enzyme, as well as probiotics and peptide ingredients. It also provides private label supplements; packaging equipment; microbial fermentation toll manufacturing and consulting services.
GeneFerm Biotechnology Co., Ltd. Fundamentals Summary
| 1796 fundamental statistics | |
|---|---|
| Market cap | NT$2.31b |
| Earnings (TTM) | NT$124.62m |
| Revenue (TTM) | NT$793.77m |
18.6x
P/E Ratio2.9x
P/S RatioIs 1796 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 1796 income statement (TTM) | |
|---|---|
| Revenue | NT$793.77m |
| Cost of Revenue | NT$507.42m |
| Gross Profit | NT$286.35m |
| Other Expenses | NT$161.73m |
| Earnings | NT$124.62m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 3.01 |
| Gross Margin | 36.07% |
| Net Profit Margin | 15.70% |
| Debt/Equity Ratio | 5.1% |
How did 1796 perform over the long term?
See historical performance and comparison